| scholarly article | Q13442814 |
| P50 | author | Julio Saez-Rodriguez | Q41044850 |
| Federica Eduati | Q47474737 | ||
| Thorsten Cramer | Q52902687 | ||
| P2093 | author name string | Christoph A Merten | |
| Mathew J Garnett | |||
| Jessica Wappler | |||
| Patricia Jaaks | |||
| P2860 | cites work | TNF-alpha induces two distinct caspase-8 activation pathways | Q24313656 |
| 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling | Q24337691 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies | Q26774636 | ||
| ON/OFF and beyond--a boolean model of apoptosis | Q28472140 | ||
| Integrative modelling of the influence of MAPK network on cancer cell fate decision | Q28534949 | ||
| Perturbation biology: inferring signaling networks in cellular systems | Q28537769 | ||
| CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms | Q30573980 | ||
| Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling | Q33507173 | ||
| Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer | Q33591673 | ||
| MEIGO: an open-source software suite based on metaheuristics for global optimization in systems biology and bioinformatics | Q33629914 | ||
| Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction | Q33668279 | ||
| The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells | Q35469548 | ||
| Dose-Response Analysis Using R. | Q35881866 | ||
| Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells | Q36095789 | ||
| A landscape of pharmacogenomic interactions in cancer. | Q37140236 | ||
| Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. | Q37196175 | ||
| Tumour cell survival signalling by the ERK1/2 pathway | Q37290943 | ||
| Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. | Q37613793 | ||
| ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence | Q37618297 | ||
| PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer | Q37655023 | ||
| Network quantification of EGFR signaling unveils potential for targeted combination therapy. | Q37660498 | ||
| mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. | Q37680565 | ||
| Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. | Q37977174 | ||
| Cancer Systems Biology: a peek into the future of patient care? | Q38184909 | ||
| Drugging the p53 pathway: understanding the route to clinical efficacy | Q38191796 | ||
| Modeling Signaling Networks to Advance New Cancer Therapies | Q38566798 | ||
| Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. | Q38708732 | ||
| Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients | Q38809615 | ||
| Comparing signaling networks between normal and transformed hepatocytes using discrete logical models | Q38925118 | ||
| PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines | Q38994024 | ||
| Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models | Q39182833 | ||
| p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). | Q42796101 | ||
| Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. | Q46575651 | ||
| Targeting mutant p53 for efficient cancer therapy. | Q47291772 | ||
| Transcription factor activities enhance markers of drug sensitivity in cancer. | Q47327751 | ||
| Methods for High-throughput Drug Combination Screening and Synergy Scoring. | Q47561424 | ||
| Boolean network-based analysis of the apoptosis network: irreversible apoptosis and stable surviving | Q47860914 | ||
| Functional precision cancer medicine-moving beyond pure genomics | Q48013156 | ||
| OmniPath: guidelines and gateway for literature-curated signaling pathway resources. | Q48190993 | ||
| The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. | Q51820596 | ||
| Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. | Q52361534 | ||
| A microfluidics platform for combinatorial drug screening on cancer biopsies. | Q55363674 | ||
| TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves | Q57082682 | ||
| Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer | Q92463662 | ||
| P433 | issue | 2 | |
| P921 | main subject | prioritization | Q11888847 |
| P304 | page(s) | e8664 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | Molecular Systems Biology | Q2261043 |
| P1476 | title | Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies | |
| P478 | volume | 16 |
| Q97525228 | Toward Systems Biomarkers of Response to Immune Checkpoint Blockers | cites work | P2860 |
Search more.